Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $402.5 million principal amount of its 1.375% convertible senior notes due 2024, including $52.5 million principal amount of notes sold pursuant to the initial purchasers’ exercise of their option to purchase additional notes. Insulet’s common stock is listed on the NASDAQ Global Select Market under the symbol “PODD.”
Insulet is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.
The Davis Polk capital markets team included partner Sophia Hudson and associate Christopher M. Bezeg. The equity derivatives team included partner Ray Ibrahim and associate Caitlin L. Wood. The tax team included partner Po Sit and associate Jonathan Atkins. Partner Pritesh P. Shah and associate Paul S. Lee provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.